Alector, Inc. Common Stock vs. Moderna, Inc. Common Stock
Alector, Inc. Common Stock and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ALEC | MRNA | |
|---|---|---|
| Market Cap | $261.28 million | $55.09 billion |
| Revenue (TTM) | $13.86 million | $2.23 billion |
| Net Income (TTM) | $-117,854,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| ALEC | MRNA | |
|---|---|---|
| Price / Book | -26.21 | 8.15 |
| Price / Sales | 18.85 | 24.73 |
ALEC leads on 2 of 2 valuation factors.
Profitability
| ALEC | MRNA | |
|---|---|---|
| Net Margin | -850.13% | -141.43% |
| Return on Equity | 1182.09% | -46.61% |
ALEC and MRNA split the profitability factors evenly.
Risk & Sentiment
| ALEC | MRNA | |
|---|---|---|
| Short Interest | 0.58% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALEC overview, ALEC financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.